PMID-28266027 – Risks of Unregulated Alpha-MSH Analogue Use
Habbema L, Halk AB, Neumann M, Bergman W. "Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review," Int J Dermatol, 2017;56(10):975-980.
Quick Reference
| Property | Value |
|---|---|
| PMID | 28266027 |
| DOI | 10.1111/ijd.13585 |
| Year | 2017 |
| Journal | International Journal of Dermatology |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (review of case reports and surveillance data) |
| Peptide(s) Studied | Melanotan II, Melanotan 1 |
Key Findings
- Comprehensive review of safety concerns associated with unregulated use of alpha-MSH analogues (Melanotan I and Melanotan II)
- Documents cutaneous complications including darkening and change in existing nevi (moles)
- Reports emergence of new dysplastic (atypical) nevi coinciding with melanotan use
- Identifies 4 cases of melanoma diagnosed in individuals using melanotan products, raising concern about potential promotion of melanocytic neoplasia
- MC1R activation stimulates melanogenesis, which may also promote proliferation of melanocytes and melanoma precursor cells
- Several countries (Norway, Denmark, UK, Ireland, Australia) have issued national health warnings against melanotan products
- Products are typically obtained online from unregulated sources with no quality control
- Additional reported adverse effects: nausea, facial flushing, fatigue, injection site reactions, priapism
Study Design
Narrative review aggregating published case reports, pharmacovigilance data, and national health authority warnings regarding the unregulated use of Melanotan I and Melanotan II. Analyzes the dermatological safety signal for melanocytic activation and potential melanoma risk.
Limitations
- Case reports cannot establish causality between melanotan use and melanoma
- Individuals seeking tanning peptides may have baseline higher UV exposure, confounding melanoma risk
- No large-scale epidemiological studies quantifying melanoma risk with melanotan use
- Cannot distinguish effects of Melanotan I vs Melanotan II in many reports
- Unregulated products may contain contaminants contributing to adverse effects
Clinical Relevance
This is an essential safety reference for practitioners. The key clinical implications are: (1) patients using Melanotan II should have baseline dermatological screening with regular mole mapping and skin cancer surveillance; (2) patients with a personal or family history of melanoma, dysplastic nevus syndrome, or fair skin types (Fitzpatrick I-II) should be counseled against melanotan use; (3) the distinction between FDA-approved afamelanotide (Scenesse, for EPP) and unregulated melanotan products must be explained to patients; (4) any new or changing moles during melanotan use require immediate dermatological evaluation. National health warnings from multiple countries add regulatory weight to safety counseling.
Related
#research #narrative-review #evidence-level-V